23 May 2022
EMA/171423/2022
European Medicines Agency

Highlights from the third meeting of the Nitrosamine Implementation Oversight Group (NIOG) and Pharmaceutical Industry

- NIOG and industry stakeholders reviewed the latest scientific developments published by CMDh/EMA and welcomed closer engagement to ensure adequate dissemination of the new scientific information arising from the call for review, which will also facilitate risk communication.
- NIOG and industry stakeholders discussed the need to accelerate the generation of scientific evidence and to promote global alignment on regulatory guidance concerning safety aspects of new nitrosamines to ensure continuity of product supply and to protect public health. This is especially relevant in the context of the upcoming conclusion of the call for review for human medicines containing chemically synthetised active substances.
- NIOG and industry stakeholders supported the convening of additional scientific meetings involving interested parties, the Quality Working Party and the Non clinical Working Party (replacing the Safety Working Party).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union